Similarly, in the female menopause subgroup, the OPG A163G polymorphism also increases the risk of osteoporosis in both non-postmenopausal women (G vs A: OR = 1.68, 95% CI = 1.36–2.07; GG vs AA: OR = 2.74, 95% CI = 1.64–4.58; AG + GG vs AA: OR = 1.37, 95% CI = 1.04–1.79; GG vs AA + AG: OR = 2.31, 95% CI = 1.55–3.43, Table 1 and Figure 2) and postmenopausal women (AG + GG vs AA: OR = 1.40, 95% CI = 1.06–1.85; GG vs AA + AG: OR = 0.67, 95% CI = 0.54–0.82, Table 1 and Figure 2). Here, TNFRSF11B is linked to osteoporosis.